Second Genome Doses First Patient In Phase 2 Clinical Study Of SGM-1019 For The Treatment Of Nonalcoholic Steatohepatitis (NASH)
January 23, 2019, South San Francisco
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Executive Officer
September 26, 2018, South San Francisco, CA
Second Genome Certified as Great Place to Work®
July 31, 2018, South San Francisco, July 30, 2018
Second Genome Appoints Anupama S. Hoey as Chief Business Officer
July 23, 2018, South San Francisco, July 23, 2018
Second Genome Presents Clinical and Preclinical Data Supporting Development of Its P2X7 Inhibitor, SGM-1019, in NASH at the EASL International Liver Congress 2018
April 9, 2018, SOUTH SAN FRANCISCO, Calif.
Second Genome Appoints Matthew W. McClure, M.D., as Chief Medical Officer
March 5, 2018, South San Francisco, CA March 5, 2018
Second Genome Strengthens R&D Program in Immuno-Oncology with Four Academic Collaborations
February 28, 2018, Feb. 28, 2018
Second Genome Advances Lead, Oral Small Molecule SGM-1019, Toward Clinical Investigation in NASH After Demonstrating Safety and Tolerability in Phase 1 Study
December 19, 2017, SOUTH SAN FRANCISCO, Calif., Dec 19, 2018
Second Genome News
